RT Journal Article
SR Electronic
T1 Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.11.23299806
DO 10.1101/2023.12.11.23299806
A1 Kac, Przemysław R.
A1 González-Ortiz, Fernando
A1 Emeršič, Andreja
A1 Dulewicz, Maciej
A1 Koutarapu, Srinivas
A1 Turton, Michael
A1 An, Yang
A1 Smirnov, Denis
A1 Kulczyńska-Przybik, Agnieszka
A1 Varma, Vijay
A1 Ashton, Nicholas J.
A1 Montoliu-Gaya, Laia
A1 Camporesi, Elena
A1 Winkel, Izabela
A1 Paradowski, Bogusław
A1 Moghekar, Abhay
A1 Troncoso, Juan C.
A1 Brinkmalm, Gunnar
A1 Resnick, Susan M
A1 Mroczko, Barbara
A1 Kvartsberg, Hlin
A1 Gregorič Kramberger, Milica
A1 Hanrieder, Jörg
A1 Čučnik, Saša
A1 Harrison, Peter
A1 Zetterberg, Henrik
A1 Lewczuk, Piotr
A1 Thambisetty, Madhav
A1 Rot, Uroš
A1 Galasko, Douglas
A1 Blennow, Kaj
A1 Karikari, Thomas K.
YR 2023
UL http://medrxiv.org/content/early/2023/12/11/2023.12.11.23299806.abstract
AB Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer’s disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Thereafter, we examined the diagnostic utility of plasma p-tau212. In five cohorts (n=388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations. The diagnostic accuracy and fold changes of plasma p-tau212 were similar to those for p-tau217 but higher than p-tau181 and p-tau231. Immunofluorescent staining of brain tissue slices showed prominent p-tau212 reactivity in neurofibrillary tangles that co-localized with p-tau217 and p-tau202/205. These findings support plasma p-tau212 as a novel peripherally accessible biomarker of AD pathophysiology.Competing Interest StatementMT and PH are employees of Bioventix Plc. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche. KB has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. NJA has given lectures in symposia sponsored by Lilly, BioArctic and Quanterix. The other authors declare no competing interest.Funding StatementPRK was funded by Demensforbundet and Anna Lisa and Brother Bjornssons Foundation. FG-O was funded by the Anna Lisa and Brother Bjornssons Foundation. LMG is supported by the Brightfocus Foundation (A2022015F), the Swedish Dementia Foundation, Gun and Bertil Stohnes Foundation, Ahlen-stifelsen, Alzheimerfonden (AF-968621) and Gamla Tjanarinnor Foundation. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2022-01018 and #2019-02397), the European Unions Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2022-0270), the European Unions Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by KB is supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721 and #AF-968270), Hjarnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG068398-01), and the Alzheimers Association 2021 Zenith Award (ZEN-21-848495). TKK was supported by the NIH (R01 AG083874-01, U24 AG082930-01, 1 RF1 AG052525-01A1, 5 P30 AG066468-04, 5 R01 AG053952-05, 3 R01 MH121619-04S1, 5 R37 AG023651-18, 2 RF1 AG025516-12A1, 5 R01 AG073267-02, 2 R01 MH108509-06, 5 R01 AG075336-02, 5 R01 AG072641-02, 2 P01 AG025204-16), the Swedish Research Council (Vetenskapradet; #2021-03244), the Alzheimers Association (#AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) Wallstroms and Mary-Ann Sjobloms stiftelsen, and the Emil och Wera Cornells stiftelsen.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed according to the Declaration of Helsinki. The Gothenburg Discovery cohort that used de-identified leftover clinical samples was approved by the ethics committees at the University of Gothenburg (#EPN140811). Studies including the Polish cohort were approved by the local ethical committee (KB-380/2017) at the University of Wroclaw. The UCSD-Neuropathology cohort was reviewed and approved by the human subject review board at UCSD. Informed consent was obtained from all patients or their caregivers consistent with California State law. The study in Slovenian cohort was approved by the Medical Ethics Committee of the Republic of Slovenia, Ministry of Health (0120-342/2021/6). The BLSA studies have ongoing approval from the Institutional Review Board of the National Institute of Environmental Health Science, National Institute of Health. Anatomical Gift Act for organ donation and a repository consent was signed by the participants to allow sharing the data and biospecimens.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBlinded Anonymized data is available on reasonable request from the corresponding author. Request will be reviewed by the investigators and respective institutions to verify if data transfer is in the agreement with EU legislation on the general data protection or is subject to any intellectual property or confidentiality obligations.